Ibrutinib,Venetoclax,obinutuzumab
Janssen,Abbvie,Roche
['lymsm', 'leusm']
long term results of ven ibrutinib and obinu showing continued excellent disease control in high risk patients with pfs 96% at 4 years #lymsm #leusm #asco22 
A hematologist @MoffittNews with interest in #lymsm. Tweets are not endorsements, and not medical advice.